ReFlow Therapeutics

About ReFlow Therapeutics

ReFlow Therapeutics, formerly known as CorFlow Therapeutics AG, is a Swiss-based medical technology company established in 2016. It was founded by Dr. Rob Schwartz, Dr. Martin Rothman, and Jon Hoem. The company is focused on developing solutions for the diagnosis and treatment of microvascular obstruction (MVO), a condition that affects over half of heart attack patients and is a significant predictor of subsequent heart failure and mortality. MVO occurs when small blood vessels in the heart muscle remain blocked even after the main artery has been cleared with a stent, impeding blood flow.

The company's core technology is the Controlled Flow Infusion (CoFI™) System. This integrated platform is engineered for use in the catheterization laboratory immediately after a stent has been placed. It provides a real-time, accurate diagnosis of MVO by measuring the heart's pressure response to controlled infusions. A key feature of the CoFI™ system is its dual capability; beyond diagnosis, it serves as a conduit for the localized delivery of therapeutic agents directly to the affected microvasculature. This ability to both detect and treat MVO in a single procedure aims to improve patient outcomes by restoring healthy microvascular blood flow. The system is designed to integrate into the standard workflow of percutaneous coronary intervention (PCI), utilizing existing guide catheters and wires. In 2019, the U.S. FDA granted the CoFI™ system a "Breakthrough Device Designation," which is intended to expedite the development and review process for medical devices that address life-threatening conditions.

ReFlow Therapeutics generates value by developing and bringing to market these specialized medical devices. Its business model relies on achieving regulatory approval and subsequent commercialization to hospitals and cardiac care centers that perform PCI procedures. The company's revenue stream will be derived from the sale of the CoFI™ system and its single-use components. To fund its research, clinical trials, and product development, the company has successfully secured significant private financing. A notable funding event was the completion of a €44 million Series B round, which was co-led by Broadview Ventures and Panakes Partners, with participation from a syndicate of international investors. This capital is allocated to support pivotal clinical studies in Europe and the US, such as the MOCA II trial, which are essential for gaining regulatory approval and demonstrating the system's efficacy and safety.